Focused On-demand Library for Cardiotrophin-like cytokine factor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9UBD9

UPID:

CLCF1_HUMAN

Alternative names:

B-cell-stimulating factor 3; Novel neurotrophin-1

Alternative UPACC:

Q9UBD9; B4DNT4; Q6NZA4

Background:

Cardiotrophin-like cytokine factor 1, also known as B-cell-stimulating factor 3 or Novel neurotrophin-1, plays a pivotal role in neuronal development and B-cell stimulation. This protein, in complex with CRLF1, forms a neurotropic cytokine heterodimer, crucial for neuronal growth and function, and activates the ILST/gp130 receptor.

Therapeutic significance:

The involvement of Cardiotrophin-like cytokine factor 1 in Crisponi/Cold-induced sweating syndrome 2, a disorder characterized by neonatal orofacial weakness and hyperhidrosis in response to cold, highlights its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to novel treatments for this rare syndrome.